Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by barcodewhizon Nov 28, 2007 1:32pm
239 Views
Post# 13881769

RE: Kedrion news posted

RE: Kedrion news posted



To me,  Kedrion's committment to acquiring Plasma collection centers in the US and outside of Italy,  tells me that they are committed to securing Plasma supply to support their Hyperimmune Project with Prometic.

From what I understand,  Kedrion has a virtual exclusive on blood collection in Italy.  But,  as part of that, they have an implied committment to keep the resulting plasma derivatives IN Italy.  Given their intention to expand the development of Hyperimmunes and other pharmaceutical applications and sell abroad,  they need to secure more plasma supply.

I think there is a lot going on behind the scenes here,  all ultimately beneficial for PLI.  We really are on the verge of significant adoption of our platform technology worldwide,  in many significant and valuable applications,  with worldwide companies. 

The key for me is to avoid being too focussed on the minutia of the very short term.   And instead ,  focus on the significant Enterprise Value growth that is going on.     I have to admit,  its easy to get shaken out of this story if youre too obsessed with the day to day... the truly patient investor will be rewarded here IMO

Bullboard Posts